GASTROENTEROLOGY ARTICLE OF THE WEEK
January 13, 2011
Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010;139:1115-1127.
1. Theoretically, PPI’s may interfere with the absorption of which of the following
a. iron
b. calcium
c. magnesium
d. riboflavin
e. vitamin C
2. Specific infections that have been linked to PPI use include
a. tuberculosis
b. C. difficile colitis
c. Hepatitis C
d. Community acquired pneumonia
e. Hosptial-acquired pneumonia
f. bacterial gastroenteritis
True or False
3. Once a day PPI’s suppress acid for 10 to 14 hours
4. Proton pump inhibitors require acid in the gastric lumen to be activated
5. Single daily dose high dose PPI therapy binds 98% of all proton pumps.
6. PPI’s inhibit cytochrome P450 2c19
7. The association between B12 malabsorption and PPI use is not clear
8. Dexlansoprazole and esomeprazole preparations result in longer serum half lives of the product that allows parietal cells to be exposed to the PPI longer
9. Dexlansoprazole MR increases the half life of the product by consisting only of the R isomer, which is metabolized slower
10. Withdrawal of PPI therapy may be a logical step in the management of a patient with persistent hypomagnesemia.
11. Symptoms from rebound acidity after stopping PPI’s can last for up to 4 weeks.